Home / Stocks / Shukra Medtech Limited
SHUKRAMED Updated about 1 hour ago

Shukra Medtech Limited Share Price

NSE closing price and which mutual funds hold this stock

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 20 Nov 2026

₹84.16

Change

+1.94 (2.36%)

Open

₹81.0

Prev. Close

₹82.22

Day High

₹84.8

Day Low

₹80.3

Volume Analysis

Traded

4,063,686

Delivered

1,994,967

Delivery %

49.09%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (3)

  • •Trading within 3% of its 52-week high (₹85.1)
  • •Strong return on equity (28.9%)
  • •Strong operating margin (58.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (49.4%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹90.38 ₹87.59 ₹85.88 ₹83.09 ₹81.38 ₹78.59 ₹76.88
Fibonacci ₹87.59 ₹85.87 ₹84.81 ₹83.09 ₹81.37 ₹80.31 ₹78.59
Camarilla ₹85.4 ₹84.99 ₹84.57 ₹83.09 ₹83.75 ₹83.34 ₹82.92

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

—

1 Month

—

3 Months

—

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹5.04

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

50.09%

Net margin 38.94% × asset turnover 0.96x × equity multiplier 1.34x

Company Overview

Sector

Healthcare

Market Cap

₹3,724 Cr

P/E (TTM)

84.0

ROE

28.9%

Book Value

₹2.69

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.

TopFund Analysis

Shukra Medtech Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹85.1); strong return on equity (28.9%). Strong 3-year EPS growth (49.4%).

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 20 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

75

Valuation

0

Cash Flow

3

Corporate Governance

60

Momentum

98

Institutional Ownership

30

Business Quality

100

Liquidity

100

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 31.3 times its book value
  • −Debtor days have increased from 123 to 148 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

NSE approved name change to Shukra Medtech Limited and symbol SHUKRAMED, effective November 20, 2026.

Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.

Reg 32 04 Nov

No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.

Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 25 19 11 3 6 11 13 5 6 39 6 24 44
Expenses + 20 9 6 2 5 7 6 4 6 12 6 4 26
Operating Profit 5 10 4 1 1 4 7 1 0 27 1 19 19
OPM % 21.0% 51.0% 41.0% 25.0% 12.0% 37.0% 55.0% 24.0% -7.0% 69.0% 11.0% 81.0% 42.0%
Other Income + 0 1 1 1 1 1 1 1 2 1 1 1 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 5 10 5 1 1 4 8 1 0 27 0 18 18
Tax % 0.0% 1.0% 24.0% 41.0% 39.0% 23.0% 29.0% 26.0% -1,090.0% 24.0% 553.0% 29.0% 29.0%
Net Profit + 5 9 4 0 1 3 5 1 2 20 -2 13 13
EPS in Rs 0 0 0 0 0 0 0 0 0 0 0 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 562 721 -76 -84 -77 — — — — 270 -52 336 652

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 TTM
Sales + 3 5 5 5 6 12 11 20 59 75 33 57 113
Expenses + 3 4 4 4 4 10 10 18 53 55 20 28 48
Operating Profit 0 1 1 2 2 2 1 3 5 19 13 29 66
OPM % -10.0% 24.0% 28.0% 30.0% 29.0% 13.0% 13.0% 14.0% 9.0% 26.0% 39.0% 51.0% 58.0%
Other Income + 1 0 0 0 0 0 0 0 1 3 4 5 3
Interest 0 0 0 0 0 0 0 0 0 0 1 1 1
Depreciation 1 0 0 1 1 1 1 2 2 2 3 3 4
Profit before tax 0 0 1 1 1 0 0 1 4 20 13 29 63
Tax % 52.0% 66.0% 52.0% 45.0% 37.0% 82.0% -90.0% 26.0% 1.0% 7.0% 28.0% 23.0% —
Net Profit + 0 0 0 1 0 0 0 1 4 19 10 22 44
EPS in Rs 0 0 0 0 0 0 0 0 0 0 0 1 1
Dividend Payout % 0.0% 0.0% 16.0% 15.0% 17.0% 0.0% 0.0% 10.0% 4.0% 6.0% 5.0% 2.0% —
Sales growth -41 85 7 4 6 109 -6 83 187 27 — 74 222

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 Sep 2026
Reserves 12 13 13 13 14 14 14 15 21 47 19 46 74
Borrowings + 1 0 0 4 6 8 10 3 5 3 4 5 22
Other Liabilities + 3 3 4 6 7 10 10 15 45 17 20 23 34
Total Liabilities 18 17 19 24 28 34 36 35 75 78 87 117 175
Fixed Assets + 10 10 10 14 16 17 18 18 20 20 19 22 21
CWIP 2 2 2 2 2 2 2 2 2 2 2 12 26
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 7 6 7 8 11 14 16 16 53 56 65 84 128
Total Assets 18 17 19 24 28 34 36 35 75 78 87 117 175
Equity Capital 2 2 2 2 2 2 2 2 4 11 44 44 44

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026
Cash from Operating Activity + -2 3 0 1 0 1 1 8 3 -5 8 3
Cash from Investing Activity + 1 0 -1 -5 -2 -3 -2 -2 -4 -1 -1 -14
Cash from Financing Activity + 1 -1 0 3 2 2 2 -7 5 12 -5 5
Net Cash Flow 0 1 -1 0 0 0 0 0 4 6 2 -6
Free Cash Flow -1 2 -1 -4 -2 -2 -1 6 -1 -7 5 -13
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 812 237 7 63 25 81 38 292 64 -24 92 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.95% → 51.16%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.92% 48.93% 48.2%
Promoters 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 51.16%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.43%
DII 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.21%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Shukra Medtech Limited (this stock) 3,724 84.0 31.3 28.9%
Shukra Pharmaceuticals L 3,639 82.1 30.56 28.9%
Unichem Laboratories Ltd 3,511 29.5 1.26 3.17%
Rpg Life Sciences Ltd 4,310 37.6 6.26 19.3%
Advanced Enzyme Tech Ltd 3,102 19.1 1.9 10.5%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Solara Active Pha Sci Ltd 3,039 64.2 2.11 -0.13%

Which Mutual Funds Hold Shukra Medtech Limited?

Frequently Asked Questions about Shukra Medtech Limited

Community Sentiment

What are other investors saying about Shukra Medtech Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.